YF Capital logo

YF Capital

Asia, Shanghai, China, Jingan

Description

Yunfeng Capital, also known as YF Capital, is a prominent private equity firm based in China, co-founded by Alibaba Group's Jack Ma and veteran investor David Yu. Established by successful entrepreneurs, the firm brings a unique, operator-centric perspective to its investment strategy, aiming to partner with companies that possess strong growth potential and innovative business models. Yunfeng Capital primarily focuses on growth equity investments, targeting late-stage companies across a diverse range of sectors including healthcare, technology, media, consumer, and financial services. Its investment philosophy emphasizes long-term value creation, often involving deep engagement with portfolio companies to support their strategic development and market expansion.

The firm has demonstrated significant fundraising capabilities and a substantial capital base, allowing it to execute large-scale investments. For instance, Yunfeng Capital's latest dollar-denominated fund, Yunfeng Capital Fund VIII, successfully closed at $3.5 billion in 2022, underscoring its continued appeal to global institutional investors. This substantial capital enables the firm to take meaningful stakes in established companies poised for significant expansion or public offerings. Their typical investment approach involves providing substantial capital injections to fuel growth, facilitate mergers and acquisitions, or support pre-IPO rounds.

Since its inception, Yunfeng Capital has amassed an impressive portfolio and has raised over $13.6 billion across 11 funds, solidifying its position as a major player in the Asian private equity landscape. The firm's deep industry knowledge, extensive network, and commitment to fostering entrepreneurial success make it a preferred partner for many high-growth companies in China and beyond. Their strategic investments aim to capitalize on the evolving economic landscape and technological advancements, driving innovation and market leadership within their chosen sectors.

Investor Profile

YF Capital has backed more than 41 startups, with 0 new investments in the last 12 months alone. The firm has led 12 rounds, about 29% of its total and boasts 31 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Series D rounds (top funding stages).
  • Majority of deals are located in China, United States, Indonesia.
  • Strong thematic focus on Biotechnology, Health Care, Medical.
  • Typical check size: $50M – $250M.

Stage Focus

  • Series B (22%)
  • Series C (20%)
  • Series D (17%)
  • Series Unknown (12%)
  • Private Equity (12%)
  • Series A (10%)
  • Series E (5%)
  • Debt Financing (2%)

Country Focus

  • China (88%)
  • United States (10%)
  • Indonesia (2%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Automotive
  • Internet
  • Manufacturing
  • Pharmaceutical
  • Medical Device
  • Information Technology
  • Logistics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does YF Capital frequently co-invest with?

Alibaba Group
Asia, Zhejiang, China, Hangzhou
Co-Investments: 6
IDG Capital
Asia, Beijing, China, Beijing
Co-Investments: 4
Tencent
Asia, Guangdong, China, Shenzhen
Co-Investments: 8
GIC
Asia, Central Region, Singapore, Singapore
Co-Investments: 4
Temasek Holdings
Asia, Central Region, Singapore, Singapore
Co-Investments: 5
5Y Capital
Asia, Shanghai, China, Xuhui
Co-Investments: 5
HongShan
Asia, Beijing, China, Beijing
Co-Investments: 11
CPE
Asia, Beijing, China, Beijing
Co-Investments: 3
Boyu Capital
Asia, Beijing, China, Beijing
Co-Investments: 3
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 3

Which angels does YF Capital often collaborate with?

WM
North America, New York, United States, New York
Shared Deals: 1

What are some of recent deals done by YF Capital?

Xreal

Beijing, Beijing, China

Xreal is a developer of lightweight and comfortable mixed reality glasses.

Augmented RealityInformation TechnologyVirtual RealityWearables
Series UnknownJan 29, 2024
Amount Raised: $60,000,000
Etana

Jakarta, Jakarta Raya, Indonesia

Etana is focused on the production and sales of biopharmaceuticals for oncology and life-threatening diseases.

BiopharmaBiotechnologyHealth CareMedicalOncologyPharmaceutical
Debt FinancingMar 20, 2023
Sironax

Beijing, Beijing, China

Sironax is a clinical-stage biotechnology company that develops novel products and treatments for age-related degenerative diseases.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Series BAug 2, 2022
Amount Raised: $200,000,000
Axbio

Shenzhen, Guangdong, China

Axbio manufactures next-generation gene sequencing and diagnostic high-end equipment and providing complete industrial solutions.

ManufacturingMedical Device
Series BJun 20, 2022
Amount Raised: $100,000,000
Robosense

Shenzhen, Guangdong, China

Robosense is an environment perception solutions provider of autonomous driving LiDAR.

ElectronicsRobotics
Series UnknownJun 14, 2022
ChangXin Memory Technologies

Hefei, Anhui, China

ChangXin Memory Technologies specializes in manufacturing dynamic random-access memory (DRAM) semiconductor products.

ElectronicsManufacturingSemiconductor
Series CFeb 17, 2022
Amount Raised: $1,183,469,301
North Ocean Photonics

Shanghai, Shanghai, China

North Ocean Photonics is a high-tech enterprise focusing on the field of micro-optics and optical integration.

HardwareOptical Communication
Series BNov 22, 2021
Dreame Technology

Suzhou, Jiangsu, China

Dreame Technology produces premium hairdryers and vacuums in the style of Dyson.

ElectronicsManufacturingRetail
Series COct 21, 2021
Amount Raised: $563,089,484
HT Aero

Tianhe, Hubei, China

HT Aero aspires to be the pioneer of urban air mobility (UAM) and is dedicated to producing safe and intelligent electric flying vehicles.

AerospaceAutomotiveElectric VehicleIntelligent Systems
Series AOct 19, 2021
Amount Raised: $500,000,000
Cellular Biomedicine Group

Palo Alto, California, United States

CBMG is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies.

BiotechnologyMedical DeviceTherapeutics
Series ASep 28, 2021
Amount Raised: $120,000,000